Kristy Sweeney-Kee, BS, RDCS, FASE, National Training Manager, and Kim Kenyon, Regional Sales Director, will be on site in Charleston, SC for the North American HFpEF Summit. We’re looking forward to supporting the meeting and connecting with attendees to share how Ultromics’ clinically validated AI is being applied within routine echocardiography to support detection of HFpEF and Cardiac Amyloidosis. #DigitalHealth #AIinHealthcare #HFpEF #Echocardiology

With expanding treatment options now available across ATTR and AL amyloidosis, early identification is critical to supporting confirmatory testing, specialist referral, and timely treatment initiation. Backed by strong peer-reviewed clinical validation, EchoGo® Amyloidosis applies AI to routine echocardiography to help identify patterns associated with cardiac amyloidosis, helping clinicians uncover signals that may otherwise go undetected and move patients toward appropriate care pathways sooner. #CardiacAmyloidosis #ATTRCM #ALAmyloidosis #AIinCardiology #CardioResearch

Cardiac amyloidosis is a life-threatening and frequently underdiagnosed condition, with up to two-thirds of amyloidosis patients missed clinically. As treatment options continue to expand across ATTR and AL amyloidosis, recognizing signs of disease sooner is increasingly important. At Ultromics, we are focused on supporting detection of complex cardiac diseases like cardiac amyloidosis through routine echocardiography, helping clinicians uncover signals that may otherwise go undetected and move patients toward appropriate care pathways sooner. #CardiacAmyloidosis #ATTRCM #ALAmyloidosis #AIinCardiology

HFpEF remains complex, underdiagnosed, and difficult to identify in standard clinical practice. With effective therapies now available, timely detection is critical to supporting appropriate evaluation, referral, and treatment pathways. EchoGo® Heart Failure applies AI to routine echocardiography to help identify patterns associated with HFpEF, backed by strong peer-reviewed clinical validation. Learn more at hubs.la/Q04k9SJ30 #ClinicalInnovation #HFpEF #HeartFailure #CardioResearch

With effective therapies now available for HFpEF, timely identification matters. HFpEF remains complex and often underdiagnosed, even with normal LVEF, making it critical to recognize patterns that may otherwise be missed. At Ultromics, we are focused on supporting detection of complex cardiac diseases like HFpEF through routine echocardiography, helping clinicians uncover insights that can guide the next step in care. #HFpEF #HeartFailure #AIinCardiology #CardioTwitter

Hear directly from physicians using EchoGo® in clinical practice. Explore real-world use cases and learn how EchoGo® integrates into echo workflows to support the detection of complex cardiac diseases, including HFpEF and cardiac amyloidosis. Read more at hubs.la/Q04jpfD-0 #EchoGo #AIinCardiology #Echocardiography #HFpEF #CardiacAmyloidosis

From scan to insight, in minutes. Ultromics connects directly with existing echocardiography workflows to analyze a standard apical 4-chamber view and identify patterns associated with HFpEF and cardiac amyloidosis. Insights are returned within the clinical workflow to support clinical decision-making, with no additional imaging or new hardware required. Seamless. Secure. Scalable. #EchoGo #AIinHealthcare #Echocardiography #HeartFailure #CardiacAmyloidosis

#ASE2026 is just one month away, and Ultromics is excited to attend! We look forward to connecting and sharing how EchoGo®, powered by AI, is being implemented in echocardiography workflows to support detection of complex cardiac diseases, including HFpEF and cardiac amyloidosis. #HeartFailure #CardiacInnovation #MedTech

Built for clinical practice. Backed by evidence. Ultromics’ EchoGo® platform supports early disease detection across HFpEF and cardiac amyloidosis, backed by strong peer-reviewed research. Designed to integrate seamlessly into existing echocardiography workflows, EchoGo® delivers AI-driven insights in minutes to augment clinical decision-making and support the appropriate care pathway. Learn more about how Ultromics' AI can impact your practice at hubs.la/Q04hGy110 #HeartFailure #ClinicalAI #HFpEF #Amyloidosis #ATTRCM

Ultromics’ AI supports early disease detection with strong peer-reviewed validation across HFpEF and cardiac amyloidosis. HFpEF → 90% sensitivity | 86% specificity Cardiac amyloidosis → 85% sensitivity | 93% specificity Learn more at ultromics.com/resources/the-… #CardioTwitter #ClinicalInnovation #ATTRCM #Amyloid #HFpEF #Cardiology

Research suggests that around 2/3 of cases may be missed using standard diagnostic approaches, despite the increased risk of heart failure hospitalization and mortality associated with delayed recognition. As the burden of complex cardiac disease continues to grow, there remains a need for tools that support early clinical consideration. Learn how EchoGo® integrates into existing echo workflows to support detection of HFpEF and cardiac amyloidosis from routine echocardiograms. 🔗hubs.la/Q04h9KrK0 #HeartFailure #HFpEF #CardiacAmyloidosis #Echocardiography #AIinHealthcare

Peer-reviewed research published in the European Heart Journal demonstrates that EchoGo® Amyloidosis outperforms traditional clinical scores, including TCAS and IWT, while maintaining consistent performance across amyloidosis subgroups. With strong diagnostic performance (85% sensitivity, 93% specificity) and low risk of bias, EchoGo® Amyloidosis supports early clinical consideration to help address persistent diagnostic delays. 🔗hubs.la/Q04gHrt00 #ATTRCM #CardiacAmyloidosis #CardiacSonography #HealthcareAI

Earlier identification is associated with reduced mortality and fewer heart failure hospitalizations, highlighting the importance of timely detection. EchoGo® Amyloidosis supports identification from routine echocardiography, helping clinicians detect signs of disease before symptoms are overlooked or dismissed. Learn more at ultromics.com/ Spencer-Bonilla G et al., JAMA Cardiol. 2026.

Physician perspectives continue to shape the conversation around AI in cardiology. The Verse highlights clinician voices, real-world implementation stories, and conversations around the role EchoGo® can play in supporting the detection of complex diseases like HFpEF and Cardiac Amyloidosis. Learn more at ultromics.com/the-verse #Echocardiography #Cardiology #AIinHealthcare #HFpEF #CardiacAmyloidosis

🔍Curious how EchoGo® can fit into your echocardiography workflow? The Verse highlights how EchoGo® is being implemented in practice—showcasing operational utility, clinical credibility, and real-world impact. From expert perspectives to real-world implementation stories, explore how Ultromics' AI is being applied to routine echocardiography. Visit hubs.la/Q04fyt7y0 to learn more! #Echocardiography #Cardiology #AIinHealthcare #HFpEF #ATTRCM

Clinical complexity can make timely detection more challenging. Ultromics’ clinically validated AI integrates into existing cardiology workflows to support detection and help guide timely next steps in care. Learn more about how EchoGo® Heart Failure and EchoGo® Amyloidosis can impact your practice, visit hubs.ly/Q04f9D4V0 #AIinHealthcare #HFpEF #ATTRCM #HealthTech

Clinical presentation can vary significantly across patient populations—making rigorous validation essential for AI tools designed to support cardiovascular care. EchoGo® is built on a foundation of robust clinical evidence, with performance validated through extensive research and peer-reviewed publications. Explore the clinical evidence: ultromics.com/hubfs/Ultromic… #AIinHealthcare #ClinicalComplexities #HFpEF #ATTRCM

HFpEF and cardiac amyloidosis often present with nonspecific symptoms, comorbidities, and subtle cardiac findings—factors that can complicate recognition in standard clinical practice. Ultromics' clinically validated AI is applied to routine echocardiography to support early detection and augment clinical evaluation for complex cardiac diseases. #HFpEF #ATTRCM #HeartFailure #DigitalHealth #AIinHealthcare

EchoGo® is validated across 25 peer-reviewed publications and is in use across leading U.S. hospitals. Designed to integrate into existing echocardiography workflows, EchoGo® Heart Failure and EchoGo® Amyloidosis deliver AI-supported insights—without disrupting clinical practice. Explore the clinical evidence: hubs.la/Q04dgcpr0 #AIinHealthcare #MedTech #DigitalHealth #HFpEF #ATTRCM

🫀 We detect from a single apical 4-chamber (A4C) view. 🩺 You interpret, confirm, and guide the next steps in care. EchoGo® applies clinically validated AI to routine echocardiography, helping surface patterns associated with HFpEF and Cardiac Amyloidosis and supporting clinical evaluation without disrupting reading workflows. We detect. You diagnose. #Echocardiography #AIinHealthcare #HFpEF #ATTRCM #DigitalHealth